A Major Randomised Trial to Determine the Value of Cisplatin-Based Chemotherapy For All Patients With Non-Small Cell Lung Cancer
OBJECTIVES: I. Assess whether the addition of cisplatin-based chemotherapy to standard
treatment improves survival in patients with non-small cell lung cancer.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. Arm
I: Patients undergo primary surgery, radical radiotherapy, radiotherapy with surgery, or
best supportive care. Arm II: Patients undergo treatment as in arm I. Beginning within 10
weeks after surgery or radical radiotherapy or as soon as possible after diagnosis, patients
receive 1 of the following regimens: Regimen A: Patients receive cisplatin IV on day 1
followed by vindesine on days 1 and 8. Regimen B: Patients receive mitomycin, ifosfamide,
and cisplatin on day 1. Regimen C: Patients receive mitomycin, vinblastine, and cisplatin on
day 1. Regimen D: Patients receive vinorelbine on days 1 and 8 and cisplatin on day 1.
Treatment in all 4 regimens repeats every 3 weeks for 3 courses. Patients are followed at 3
months, 6 months, 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 1,800 patients will be accrued for this study within 3 years.
Allocation: Randomized, Primary Purpose: Treatment
Stephen G. Spiro
University College London Hospitals
United States: Federal Government